Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 50,439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Clear all

Conditions: Lung Cancer, Lung Neoplasms, Cancer of Lung, Cancer of the Lung, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms, Carcinoma, Non-small-cell Lung, Adenocarcinoma, Squamous Cell Carcinoma
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis, Radiation Toxicity, Xerostomia
Interventions: Amifostine, Carboplatin, Paclitaxel, radiation; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 9
States / cities: Sanford, Maine • Boston, Massachusetts • Concord, Massachusetts + 4 more

Conditions: Biopsy Proven Non Small Cell Lung Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Colorectal Cancer, Rectal Cancers, Gynecological Malignancy Requiring Definitive Radiotherapy
Interventions: CT scan; Diagnostic Test
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cetuximab, molecular diagnostic method, immunologic technique, laboratory biomarker analysis; Biological · Genetic · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Cushing's Disease
Interventions: Pasireotide sub-cutaneous; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 17
States / cities: Peoria, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more

Conditions: B-cell Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions: alemtuzumab, rituximab, fludarabine phosphate; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 2
States / cities: Chicago, Illinois • Columbus, Ohio

Conditions: Polycythemia Vera, Thrombocythemia
Interventions: CC-4047, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fibrolamellar Carcinoma, Fibrolamellar Liver Cancer
Interventions: everolimus, letrozole plus leuprolide, combination of everolimus, letrozole and leuprolide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 6
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Cranial Nerve Disorder, Head and Neck Carcinoma, Oropharyngeal Carcinoma
Interventions: Methylprednisolone, Prednisone, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumors
Interventions: BIIB022; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 3
States / cities: Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania

Conditions: Fanconi Anemia, Head and Neck Cancer, Squamous Cell Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN)
Interventions: Metformin, Naproxen Sodium; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Minneapolis, Minnesota • New York, New York

Conditions: Kidney Neoplasms
Interventions: Thalidomide, Capecitabine; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Stanford, California

Conditions: Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
Interventions: 1.0% IP-001 for Injection; Drug
Lead sponsor: Immunophotonics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Coral Gables, Florida • Louisville, Kentucky • Oklahoma City, Oklahoma

Conditions: Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Urothelial Carcinoma, Non-small Cell Lung Cancer
Interventions: ONM-100; Drug
Lead sponsor: OncoNano Medicine, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Dallas, Texas • Houston, Texas

Conditions: Neoplasm Malignant
Interventions: SAR405838; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York

Conditions: Melanoma (Skin)
Interventions: aldesleukin, sargramostim, adjuvant therapy; Biological · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Colorectal Polyp, Colorectal Cancer, T1 Colorectal Cancer
Interventions: Questionnaires; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Melanoma
Interventions: GM-CSF, Standard of Care; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8
Interventions: Near Infrared Imaging, Therapeutic Conventional Surgery, Tozuleristide; Procedure · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lymphoma, Infection, Leukemia
Interventions: Fluconazole, Voriconazole; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 2 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 33
States / cities: Birmingham, Alabama • La Jolla, California • Stanford, California + 25 more

Conditions: Coronary Artery Disease, Cardiac Disease, Malignancy, Second
Interventions: Not listed
Lead sponsor: LMU Klinikum; Other
Eligibility: 18 Years and older
Enrollment: 4,502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Small Cell Carcinoma of Lung, Colorectal Cancer, Hormone Receptor Positive Breast Carcinoma
Interventions: AVA6103; Drug
Lead sponsor: Avacta Life Sciences Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Scottsdale, Arizona • Sarasota, Florida • Chicago, Illinois + 4 more

Conditions: Advanced Solid Tumor
Interventions: STX-003, KEYTRUDA®; Biological
Lead sponsor: Strand Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Nashville, Tennessee

Conditions: Ovarian Cancer, Peritoneal Cancer
Interventions: pemetrexed; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer

Randomized Amifostine For SCCHN

A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy

Cetuximab in Treating Patients With Advanced Solid Tumors

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Pomalidomide for Myelofibrosis Patients

Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)

High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia

A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer

Phase 1 Safety Testing of SAR405838

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Malignant Polyp Registry

Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)

Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer